Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v10-FR Version v6-FR
Language French French
Date Updated 2019-06-12 2019-04-15
Drug Identification Number 02337436 02337436
Brand name SANDOZ IRBESARTAN HCT SANDOZ IRBESARTAN HCT
Common or Proper name IRBESARTAN HCT IRBESARTAN HCT
Company Name SANDOZ CANADA INCORPORATED SANDOZ CANADA INCORPORATED
Ingredients HYDROCHLOROTHIAZIDE IRBESARTAN HYDROCHLOROTHIAZIDE IRBESARTAN
Strength(s) 12.5MG 300MG 12.5MG 300MG
Dosage form(s) TABLET TABLET
Route of administration ORAL ORAL
Packaging size 100 100
ATC code C09DA C09DA
ATC description ANGIOTENSIN II ANTAGONISTS, COMBINATIONS ANGIOTENSIN II ANTAGONISTS, COMBINATIONS
Reason for shortage Requirements related to complying with good manufacturing practices. Requirements related to complying with good manufacturing practices.
Anticipated start date
Actual start date 2018-11-01 2018-11-01
Estimated end date 2019-09-30 2019-05-27
Actual end date
Shortage status Actual shortage Actual shortage
Company comments
Health Canada comments